Enjoy these illustrated stories and learn more about key topics, practices and protocols.

The underestimated role of placental growth factor (PlGF)

Aflibercept binds several vascular permeability factors, namely VEGF-A, VEGF-B and PlGF. What is the role of PlGF and its receptor system in retinal vascular diseases, and why targeting also this factor is an added value to the therapy?

The PULSAR and PHOTON trials

The pivotal PULSAR and PHOTON trials have demonstrated the safety and efficacy of aflibercept 8 mg with extended intervals in wet AMD and DME, respectively. Michael Stewart, MD, explains the trials in detail.

Treat & Extend in ME secondary to CRVO

In the CENTERA study, significant functional and anatomic improvements were achieved by treating macular edema (ME) secondary to central retinal vein occlusion (CRVO) with a treat-and-extend (T&E) dosing regimen. Varun Chaudhary, leading author of the study, explains why T&E might be an ideal approach in these patients.

Myopic CNV

The management of myopic CNV, explained by Paolo Lanzetta.

Treat & Extend

The T&E dosing regimen, and the advantages of this treatment modality for patients and physicians, explained by Gemmy Cheung.

To switch or not to switch?

An expert guide in how to deal with poor response to anti-VEGF in diabetic macula edema.

Which anti-VEGF treatment regimen?

Intravitreal anti-vascular endothelial growth factor agents, such as aflibercept, ranibizumab, and bevacizumab, have revolutionised the way neovascular retinal diseases are managed. However, there are still questions about the most effective dosing schedule for these medications to help optimise treatment effect and patient experience. Here, Sebastian Wolf highlights the key differences between the most commonly used dosing schedule.

DRCR.net Protocol T study: 1- and 2-year results

Sanjay Sharma gives an overview of both the 1- and 2-year results from the DRCR.net Protocol T study comparing aflibercept, ranibizumab and bevacizumab.

HFMEA explained

An animated explanation of HFMEA and IVEG narrated by Paolo Lanzetta.